$A phase 1 study of eribulin mesylate (E7389), a novel microtubule‐targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314)$

A phase 1 study of eribulin mesylate (E7389), a novel microtubule‐targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314)

Background Eribulin mesylate is a novel anticancer agent that inhibits microtubule growth, without effects on shortening, and promotes nonproductive tubulin aggregate formation. We performed a phase 1 trial to determine the dose‐limiting toxicities (DLTs), maximum tolerated or recommended phase 2 do...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pediatric blood & cancer 2018-08, Vol.65 (8), p.e27066-n/a
Hauptverfasser:	Schafer, Eric S., Rau, Rachel E., Berg, Stacey, Liu, Xiaowei, Minard, Charles G., D'Adamo, David, Scott, Rachael, Reyderman, Larisa, Martinez, Gresel, Devarajan, Sandhya, Reid, Joel M., Fox, Elizabeth, Weigel, Brenda J., Blaney, Susan M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Anorexia Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Central nervous system Child Child, Preschool Children Dose-Response Relationship, Drug Drug Resistance, Neoplasm - drug effects eribulin Ewing's sarcoma Fatigue Female Furans - administration & dosage Furans - adverse effects Furans - pharmacokinetics Hematology Humans Hypokalemia Ketones - administration & dosage Ketones - adverse effects Ketones - pharmacokinetics Lymphopenia Male Maximum Tolerated Dose Microtubules - drug effects Nausea Neoplasm Recurrence, Local - drug therapy Neoplasms - drug therapy Neutropenia Oncology Pediatrics Peripheral neuropathy Pharmacokinetics Phase 1 Prolongation Sarcoma Solid tumors Toxicity Tubulin
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!